Ractigen Therapeutics, a Nantong, China-based RNAa technology company, closed a Series A+ financing round totaling $30m.
The round was led by SDIC Venture Capital with participation from Eisai Co., Ltd., LC Ventures, CSSD Capital, and Xianghe Capital.
The company will use the funds to advance several programs from preclinical to clinical phase, as well as scale-up its oligonucleotide manufacturing capabilities.
Founded in 2017 by pioneers of the RNAa technology including Dr. Long-Cheng Li and his longstanding colleagues Dr. Robert Place and Dr. Moorim Kang, Ractigen is a late-stage preclinical pharmaceutical company devoted to creating therapies based on the RNAa platform. RNAa utilizes short duplex RNAs, known as small activating RNAs (saRNA), to specifically up-regulate targeted endogenous genes for boosting therapeutic protein production. Supporting its core platform, The company has created the SCAD delivery system allowing enhanced biodistribution throughout extrahepatic tissue and built a rich pipeline of first-in-class candidate medicines for patients with unmet genetic disorders.
FinSMEs
28/01/2022